Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

VANDA PHARMACEUTICALS INC.

(VNDA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
12.7(c) 13.37(c) 13.45(c) 13.42(c) 12.195(c) Last
264 140 490 135 396 793 294 632 958 784 Volume
-1.93% +5.28% +0.60% -0.22% -9.13% Change
More quotes
Financials (USD)
Sales 2019 226 M
EBIT 2019 32,3 M
Net income 2019 121 M
Debt 2019 -
Yield 2019 -
Sales 2020 275 M
EBIT 2020 105 M
Net income 2020 75,7 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 5,62x
P/E ratio 2020 15,7x
Capi. / Sales2019 2,88x
Capi. / Sales2020 2,37x
Capitalization 650 M
More Financials
Company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It... 
Sector
Biotechnology & Medical Research
Calendar
02/25 | 04:30pmEarnings Call
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : - Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
02/19VANDA PHARMACEUTICALS : Appoints Stephen Ray Mitchell to Board of Directors
PR
02/19VANDA PHARMACEUTICALS INC. : Change in Directors or Principal Officers, Financia..
AQ
02/18VANDA PHARMACEUTICALS : to Announce Fourth Quarter and Full Year 2019 Financial ..
PR
02/03VANDA PHARMACEUTICALS : Comments on Court Ruling
AQ
02/03VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
01/31VANDA PHARMACEUTICALS : Comments on Court Ruling
PR
01/14VANDA PHARMACEUTICALS : Wins Key U.S. Supreme Court Patent Ruling on Fanapt
AQ
01/13VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
01/13VANDA PHARMACEUTICALS : Wins Key U.S. Supreme Court Patent Ruling on Fanapt®
PR
2019VANDA PHARMACEUTICALS : Mihael H. Polymeropoulos, MD, President and CEO of Vanda..
PR
2019VANDA PHARMACEUTICALS : Announces Participation at November 2019 Investor Confer..
PR
2019VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
AQ
2019VANDA : 3Q Earnings Snapshot
AQ
2019VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
AQ
2019VANDA PHARMACEUTICALS : Reports Third Quarter 2019 Financial Results
PR
More news
News in other languages on VANDA PHARMACEUTICALS INC.
2014Wall Street ouvre en hausse, le Dow franchit les 18.000 points
2014Les valeurs à suivre sur les marchés américains
2013VANDA PHARMACEUTICALS INC. : publication des résultats trimestriels
More news
Analyst Recommendations on VANDA PHARMACEUTICALS INC.
More recommendations
Sector news : Bio Therapeutic Drugs
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Bio Therapeutic Drugs
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VANDA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 28,20  $
Last Close Price 12,20  $
Spread / Highest target 326%
Spread / Average Target 131%
Spread / Lowest Target 39,4%
EPS Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
Michael F. Cola Independent Director
Richard W. Dugan Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS INC.-25.69%650
GILEAD SCIENCES3.11%88 181
VERTEX PHARMACEUTICALS12.49%63 855
REGENERON PHARMACEUTICALS6.30%43 886
WUXI APPTEC CO., LTD.22.35%26 379
GENMAB14.61%16 125